How should leg stiffness that began after initiating semaglutide therapy be evaluated and managed?

Leg Stiffness After Starting Semaglutide: Evaluation and Management

Leg stiffness that develops after initiating semaglutide is not a recognized adverse effect in FDA labeling or major clinical guidelines, and requires systematic evaluation to exclude serious neuromuscular complications, nutritional deficiencies, or coincidental conditions rather than assuming a direct drug relationship.

Clinical Approach

Immediate Assessment Priorities

The provided evidence does not list leg stiffness as a documented adverse effect of semaglutide in FDA labeling 1 or in the 2025 AACE obesity guidelines 2. However, emerging case reports describe serious musculoskeletal complications that may present with leg symptoms:

Critical red flags requiring urgent evaluation:

• Progressive proximal muscle weakness - May indicate immune-mediated necrotizing myopathy (IMNM), reported in one case following semaglutide exposure 3
• Severe bilateral lower extremity weakness with sensory changes - Consider lumbosacral polyradiculopathy from micronutrient deficiencies, particularly if combined with other weight-loss interventions 4
• Dark urine, muscle pain, or cramping - Evaluate for rhabdomyolysis, reported with dose escalation to 2.4 mg 5

Diagnostic Workup

Laboratory evaluation should include:

• Creatine kinase (CK) - to exclude rhabdomyolysis (normal: 20-200 U/L; case report showed 16,202 U/L) 5
• Comprehensive metabolic panel with liver enzymes
• Micronutrient assessment - thiamine, vitamin E, vitamin B12, vitamin D, folate (especially critical if patient has history of bariatric surgery or rapid weight loss) 4
• Consider inflammatory markers if myopathy suspected

Clinical examination specifics:

• Assess for proximal vs. distal weakness pattern
• Test deep tendon reflexes (loss suggests polyradiculopathy)
• Evaluate sensory distribution
• Document functional limitations (chair rise test, gait speed)

Mechanism Considerations

While leg stiffness is not established as a semaglutide effect, several pathophysiologic possibilities exist:

Muscle volume loss: Semaglutide causes significant muscle volume reduction (9.3% psoas volume decrease over 24 weeks) 6, though physical function typically remains preserved. However, rapid muscle loss could theoretically contribute to stiffness or weakness sensations.

Nutritional depletion: GLP-1 receptor agonists suppress appetite substantially. When combined with other weight-loss interventions or in patients with marginal nutritional status, severe micronutrient deficiencies can develop, manifesting as neuromuscular symptoms 4.

Rare immune phenomena: One case report documents IMNM following a single semaglutide dose, with progressive symptoms over 4 months 3. While extremely rare, this represents a potentially serious complication requiring immunosuppression.

Management Algorithm

If CK is markedly elevated (>1000 U/L):

1. Stop semaglutide immediately
2. Initiate aggressive IV hydration
3. Monitor renal function closely
4. Investigate other rhabdomyolysis triggers (statins, recent trauma, metabolic disorders)

If micronutrient deficiencies identified:

1. Discontinue or hold semaglutide until nutritional status optimized
2. Initiate targeted supplementation (thiamine, vitamin E as indicated)
3. Consider inpatient rehabilitation if severe weakness present 4
4. Avoid restarting GLP-1 therapy until deficiencies corrected and patient stabilized

If IMNM suspected (progressive weakness, elevated CK, inflammatory infiltrate):

1. Permanently discontinue semaglutide
2. Rheumatology consultation for muscle biopsy
3. Initiate corticosteroids and IVIG if confirmed 3

If workup negative and symptoms mild:

1. Consider dose reduction - Many adverse effects are dose-dependent 7
2. Ensure adequate protein intake (1.2-1.6 g/kg/day) to preserve muscle mass
3. Implement resistance exercise program
4. Monitor symptoms closely with 2-4 week follow-up
5. If symptoms persist or worsen despite conservative measures, discontinue semaglutide and reassess

Critical Pitfalls to Avoid

Do not assume benign etiology without workup. While most semaglutide adverse effects are gastrointestinal 8, 9, 8, the case reports of rhabdomyolysis 5, IMNM 3, and severe polyradiculopathy 4 demonstrate that serious neuromuscular complications can occur.

Do not overlook nutritional screening, especially in patients with:

• History of bariatric surgery
• Rapid weight loss (>1-2 kg/week)
• Multiple concurrent weight-loss interventions
• Pre-existing marginal nutritional status

Do not restart semaglutide if serious complications (rhabdomyolysis, IMNM, severe deficiency-related neuropathy) are confirmed. These represent contraindications to rechallenge.

Consider alternative GLP-1 formulations cautiously. The IMNM case report suggests potential class effect 3, though evidence is extremely limited. If switching is considered after resolution of symptoms, use lowest effective dose with intensive monitoring.

Evidence Limitations

The provided guidelines 2 and FDA labeling 1 do not specifically address leg stiffness. The case reports 5, 3, 4 represent rare events and cannot establish causation definitively. However, the temporal relationship, dose-response patterns (particularly for rhabdomyolysis 5), and biological plausibility warrant serious consideration in clinical practice.